TAHO History
- 2024 Patent Allowed US:TAH3311 Anticagulant Oral Film
- 2023 Patent Allowed EU:TAH4411 Ondansetron OD Film 'Present TAH33 antithrombotic series projects research findings and conduct business matchmaking at the BIO International Convention in the United States. 'Invited to present innovative Trans-Epithelial Drug Delivery platform technology at BIO-Europe and Biopharma America.
- 2022 Completion of Phase 1 clinical study of TAH3311 Anticagulant Oral Film in US
Won the 2022 Taipei Biotech Award Special Medal in Innovation
Patent Allowed
US:TAH9922 ADHD Atomoxetine Oral Liq
- 2021 Completion of Phase 1 Study of TAH3311 Anticoagulant Oral Film in Canada
Patent Allowed
US: TAH6601 Epilepsy patch; China: TAH4411 Ondansetron OD Film; Taiwan: TAH3301 Anticoagulant patch ; Hong Kong: TAH9901 ADHD Methylphenidate Transdermal Patch
- 2020 Patent Allowed
- 2019 Out-licensed TAH9922 Atomoxetine Oral Liq for US market
Patent Allowed
US: TAH9901 ADHD Methylphenidate Transdermal Patch 3rd US patent
- 2018 TAH4411 OD Film received first Ondansetron Oral Film approval in Japan
US: TAH9901 ADHD Methylphenidate Transdermal Patch 2nd US patent, TAH9922 ADHD Atomoxetine Oral Liq 2nd US patent; Taiwan: TAH9922 ADHD Atomoxetine Oral Liq
- 2017 Patent Allowed
- 2016 TAH9901 ADHD Methylphenidate Transdermal Patch was awarded 13th National Innovation Award by IBMI.
- 2015 Completion of TAH4411 Ondansetron OD Film Clinical Study
- 2013 Granted the Gold Award in the 12th Ministry of Economic Affairs Business Startup Award.
- 2010 TAHO was founded in Taipei, Taiwan